<th id="ltdhy"><pre id="ltdhy"></pre></th>

<s id="ltdhy"></s>
    1. <rp id="ltdhy"><object id="ltdhy"><input id="ltdhy"></input></object></rp><progress id="ltdhy"><pre id="ltdhy"></pre></progress>

      <button id="ltdhy"><object id="ltdhy"></object></button>

      <progress id="ltdhy"><track id="ltdhy"></track></progress>

    2. <span id="ltdhy"><pre id="ltdhy"></pre></span>

      1. 
        

        1. <rp id="ltdhy"></rp>

          1. Entries by

            JYSELECA? (FILGOTINIB) FOR RHEUMATOID ARTHRITIS LAUNCHES IN JAPAN

            Gilead Sciences K.K. (Head office: Chiyoda-ku, Tokyo; President and Representative Director: Luc Hermans; “Gilead”) and Eisai Co., Ltd. (Head office: Bunkyo-ku, Tokyo, CEO: Haruo Naito; “Eisai”) today announced that Jyseleca??(filgotinib maleate 200 mg and 100 mg tablets), a new once-daily, oral, JAK (Janus kinase) inhibitor that preferentially inhibits JAK1, will be launched in Japan on November 18 for the treatment of rheumatoid arthritis (RA), with prior regulatory approval by the Japanese Ministry of Health, Labour and Welfare.

            EISAI SELECTED FOR MEMBERSHIP IN DOW JONES SUSTAINABILITY ASIA PACIFIC INDEX 2020 FOR SEVENTH TIME

            Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that it has been selected for a membership in the Dow Jones Sustainability Asia Pacific Index (DJSI Asia Pacific), the Asia Pacific version of the Dow Jones Sustainability Indices (DJSI), which are a family of premier global indices for socially responsible investment (SRI). This marks Eisai’s seventh selection.

            久久人人97超碰超国产,天天摸夜夜添夜夜无码,久久精品人人槡人妻人人玩,97碰碰碰人妻无码视频